Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of IPO & Placements for Aequitas Research. At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%. 
Prior to Aequitas. I was heading Content Strategy for Smartkarma, along with covering IPOs & Placement. In an earlier life I have covered ASEAN property and the banking space in India.

Head of Research, IPOs & Placements

Wuxi Biologics Placement - Well Ahead of Lock-Up, Again

Wuxi Biologics Placement - Laying the Groundwork for Future Growth

Pre-IPO BeiGene - Would the IPO on the STAR Market Be the Last Hurrah?

Wuxi Biologics - Recap/Learnings from past Placements

Wuxi Biologics Placement - This Time It's Different

Wuxi Biologics Placement - Biggest Deal Size at Launch, Well Ahead of Lock-Up Expiry

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<div>
<p>Wuxi Biologics Holdings is looking to raise up to US$800m by selling 2.4% of <a href="https://www.smartkarma.com/entities/wuxi-apptec" target="_blank" data-smartkarma-citation="entities:23679:1" rel="noopener">Wuxi Biologics (Cayman) Inc (2269 HK)</a>.  This is the 11th placement in the name since it listed in Jun 2017.</p>
<p>Most of the past deals have done well. </p>
<div><p>Links to our coverage of the IPO and past deals:</p></div>
</div><div><ul style="list-style-type: disc;">
<li>Jun 2017 - US$500m: <a href="https://www.smartkarma.com/insights/wuxi-biologics-ipo-review-an-opportunity-to-get-exposure-to-biologics-in-china" target="_blank" rel="noopener">WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China</a>
</li>
<li>Dec 2017- US$650m: <a href="https://www.smartkarma.com/insights/wuxi-biologics-placement-selldown-right-when-lockup-expires-suggests-eagerness-to-offload" target="_blank" rel="noopener">Wuxi Biologics Placement - Selldown Right when Lockup Expires Suggests Eagerness to Offload</a>
</li>
<li>Mar 2018 - US$605m: <a href="https://www.smartkarma.com/insights/wuxi-biologics-placement-in-time-for-the-next-lock-up-returns-will-probably-not-match-prior-ones" target="_blank" rel="noopener">Wuxi Biologics Placement - In Time for the Next Lock-Up, Returns Will Probably Not Match Prior Ones</a>
</li>
<li>Jun 2018 - US$510m: <a href="https://www.smartkarma.com/insights/wuxi-biologics-placement-probably-not-a-surprise-to-sell-again-when-lock-up-expires" target="_blank" rel="noopener">Wuxi Biologics Placement - Probably Not a Surprise to Sell Again when Lock-Up Expires</a>
</li>
<li>Mar 2019 - US$517m: <a href="https://www.smartkarma.com/insights/wuxi-biologics-placement-past-deals-have-done-well-but-progressive-returns-are-getting-lower" target="_blank" rel="noopener">Wuxi Biologics Placement - Past Deals Have Done Well but Progressive Returns Are Getting Lower</a>
</li>
<li>June 2019 - US$495m: <a href="https://www.smartkarma.com/insights/wuxi-biologics-placement-past-deal-did-well-despite-sell-down-overhang" target="_blank" rel="noopener">Wuxi Biologics Placement: Past Deal Did Well Despite Sell-Down Overhang</a>
</li>
<li>October 2019 - US$1,020m: <a href="https://www.smartkarma.com/insights/wuxi-biologics-placement-a-larger-deal-but-performance-track-record-weighs" target="_blank" rel="noopener">Wuxi Biologics Placement: A Larger Deal but Performance Track Record Weighs</a>
</li>
<li>Jan 2020 - US$753m: <a href="https://www.smartkarma.com/insights/wuxi-biologics-placement-almost-all-of-the-past-deals-have-done-well-would-bid-near-the-bottom-end" target="_blank" rel="noopener">Wuxi Biologics Placement: Almost All of the past Deals Have Done Well, Would Bid near the Bottom End</a>
</li>
<li>Mar 2020 - US$599m: <a href="https://www.smartkarma.com/insights/wuxi-biologics-placement-another-pre-lockup-placement-but-past-deals-have-done-well" target="_blank" data-smartkarma-citation="insights:37994" rel="noopener">Wuxi Biologics Placement: Another Pre-Lockup Placement but Past Deals Have Done Well</a> </li>
<li>May 2020 - US$984m: <a href="https://www.smartkarma.com/insights/wuxi-biologics-placement-biggest-deal-size-at-launch-well-ahead-of-lock-up-expiry" target="_blank" rel="noopener">Wuxi Biologics Placement - Biggest Deal Size at Launch, Well Ahead of Lock-Up Expiry</a>
</li>
<li>Jun 2020 - US$798m: <a href="https://www.smartkarma.com/insights/wuxi-biologics-placement-this-time-it-s-different" target="_blank" rel="noopener">Wuxi Biologics Placement - This Time It’s Different</a>
</li>
<li>Round-up of past deals performance - <a href="https://www.smartkarma.com/insights/wuxi-biologics-recap-learnings-from-past-placements" target="_blank" rel="noopener">Wuxi Biologics - Recap/​Learnings from past Placements</a>
</li>
</ul></div>


Wuxi Biologics Holdings is looking to raise up to US$800m by selling 2.4% of Wuxi Biologics (Cayman) Inc (2269 HK).  This is the 11th placement in the name since it listed in Jun 2017.
Most of the past deals have done well. 
Links to our coverage of the IPO and past deals:

Jun 2017 - US$500m: WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China

Dec 2017- US$650m: Wuxi Biologics Placement - Selldown Right when Lockup Expires Suggests Eagerness to Offload

Mar 2018 - US$605m: Wuxi Biologics Placement - In Time for the Next Lock-Up, Returns Will Probably Not Match Prior Ones

Jun 2018 - US$510m: Wuxi Biologics Placement - Probably Not a Surprise to Sell Again when Lock-Up Expires

Mar 2019 - US$517m: Wuxi Biologics Placement - Past Deals Have Done Well but Progressive Returns Are Getting Lower

June 2019 - US$495m: Wuxi Biologics Placement: Past Deal Did Well Despite Sell-Down Overhang

October 2019 - US$1,020m: Wuxi Biologics Placement: A Larger Deal but Performance Track Record Weighs

Jan 2020 - US$753m: Wuxi Biologics Placement: Almost All of the past Deals Have Done Well, Would Bid near the Bottom End

Mar 2020 - US$599m: Wuxi Biologics Placement: Another Pre-Lockup Placement but Past Deals Have Done Well 
May 2020 - US$984m: Wuxi Biologics Placement - Biggest Deal Size at Launch, Well Ahead of Lock-Up Expiry

Jun 2020 - US$798m: Wuxi Biologics Placement - This Time It’s Different

Round-up of past deals performance - Wuxi Biologics - Recap/​Learnings from past Placements



Wuxi Biologics Placement - Another One Before Lock-Up, but Just in Time for the Index Inclusion